Human T-cell leukemia virus-associated malignancy

Current Opinion in Virology

Volumn 20, Issue , 2016, Pages 40-46

  Panfil, Amanda R ^a   Martinez, Michael P ^a   Ratner, Lee ^b   Green, Patrick L ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLIC ACID ANTAGONIST; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; PREDNISONE; PROTEASOME INHIBITOR; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; RANIMUSTINE; VINCRISTINE; VINDESINE; ZIDOVUDINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CLINICAL CLASSIFICATION; HTLV-1 INFECTION; HUMAN; HUMAN T-LYMPHOTROPIC VIRUS 1; LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SPINAL CORD DISEASE; SURVIVAL RATE; SYMPTOM; T CELL LEUKEMIA; T CELL LYMPHOMA; TROPICAL SPASTIC PARAPARESIS; VIRUS GENOME; VIRUS TRANSMISSION; WATCHFUL WAITING; COMPLICATION; PATHOPHYSIOLOGY;

CARCINOGENESIS; HTLV-I INFECTIONS; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL;

EID: 84984686660     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.08.009     Document Type: Review

References (85)

1. 1 Matsuoka, M., Jeang, K.T., Human T-cell leukemia virus type I at age 25: a progress report. Cancer Res 65 (2005), 4467–4470.
2. 2 DeThe, G., Bomford, R., An HTLV-I vaccine: why, how, for whom?. AIDS Res Hum Retroviruses 9 (1993), 381–386.
3. 3 Gessain, A., Cassar, O., Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol, 3, 2012, 388.
4. 4 Kohakura, M., et al. Seroepidemiology of the human retrovirus (HTLV/ATLV) in Okinawa where adult T-cell leukemia is highly endemic. Jpn J Cancer Res: Gann 77 (1986), 21–23.
5. 5 Tajima, K., et al. Epidemiological features of HTLV-I carriers and incidence of ATL in an ATL-endemic island: a report of the community-based co-operative study in Tsushima, Japan. Int J Cancer 40 (1987), 741–746.
6. 6 Yoshida, M., Miyoshi, I., Hinuma, Y., Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 79 (1982), 2031–2035.
7. 7 Igakura, T., et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 299 (2003), 1713–1716.
8. 8 Barnard, A.L., et al. Engagement of specific T cell surface molecules regulates cytoskeletal polarization in HTLV-1-infected lymphocytes. Blood, 2005.
9. 9 Derse, D., et al. Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors. J Virol 75 (2001), 8461–8468.
10. 10 Mazurov, D., et al. Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors. PLoS Pathogens, 6, 2010, e1000788.
11. 11 Takahashi, K., et al. Inhibitory effect of maternal antibody on mother-to-child transmission of human T-lymphotropic virus type I. The Mother-to-Child Transmission Study Group. Int J Cancer 49 (1991), 673–677.
12. 12 Hino, S., et al. Intervention of maternal transmission of HTLV-1 in Nagasaki, Japan. Leukemia 8:Suppl 1 (1994), S68–S70.
13. 13 Ureta-Vidal, A., et al. Mother-to-child transmission of human T-cell-leukemia/lymphoma virus type I: implication of high antiviral antibody titer and high proviral load in carrier mothers. Int J Cancer 82 (1999), 832–836.
14. 14• Carneiro-Proietti, A.B., et al. Mother-to-child transmission of human T-cell lymphotropic viruses-1/2: what we know, and what are the gaps in understanding and preventing this route of infection. J Pediatr Infect Dis Soc 3:Suppl 1 (2014), S24–S29 The authors review what is currently known concerning HTLV-1 maternal transmission and discuss methods for prevention.
15. 15 Suzuki, S., et al. Prevalence of human T-cell leukemia virus type 1 carrier in Japanese pregnant women in 2013. J Clin Med Res 7 (2015), 499–500.
16. 16 Kashiwagi, K., et al. A decrease in mother-to-child transmission of human T lymphotropic virus type I (HTLV-I) in Okinawa, Japan. Am J Trop Med Hyg 70 (2004), 158–163.
17. 17 Mylonas, I., et al. HTLV infection and its implication in gynaecology and obstetrics. Arch Gynecol Obstet 282 (2010), 493–501.
18. 18 Nakano, S., et al. Search for possible routes of vertical and horizontal transmission of adult T-cell leukemia virus. Gann 75 (1984), 1044–1045.
19. 19 Tajima, K., et al. Epidemiological analysis of the distribution of antibody to adult T-cell leukemia-virus-associated antigen: possible horizontal transmission of adult T-cell leukemia virus. Gann 73 (1982), 893–901.
20. 20 Murphy, E.L., et al. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 111 (1989), 555–560.
21. 21 Kaplan, J.E., et al. Male-to-female transmission of human T-cell lymphotropic virus types I and II: association with viral load. The Retrovirus Epidemiology Donor Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 12 (1996), 193–201.
22. 22 Roucoux, D.F., et al. A prospective study of sexual transmission of human T lymphotropic virus (HTLV)-I and HTLV-II. J Infect Dis 191 (2005), 1490–1497.
23. 23 Kajiyama, W., et al. Intrafamilial transmission of adult T cell leukemia virus. J Infect Dis 154 (1986), 851–857.
24. 24 Sullivan, M.T., et al. Transmission of human T-lymphotropic virus types I and II by blood transfusion: a retrospective study of recipients of blood components. Arch Intern Med 151 (1991), 2043–2048.
25. 25 Okochi, K., Sato, H., Hinuma, Y., A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang 46 (1984), 245–253.
26. 26 Manns, A., et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 51 (1992), 886–891.
27. 27• Hewagama, S., et al. Human T-cell lymphotropic virus type 1 exposures following blood-borne virus incidents in central Australia, 2002–2012. Clin Infect Dis 59 (2014), 85–87 This is the first detailed, published report on occupational exposure to HTLV-1. The authors retrospectively examined hospital occupational exposure events over a 10-year period in Central Australia, finding no transmission of HTLV-1 in 53 exposed individuals.
28. 28 Kataoka, R., et al. Transmission of HTLV-I by blood transfusion and its prevention by passive immunization in rabbits. Blood 76 (1990), 1657–1661.
29. 29 Derse, D., et al. Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses. J Virol 81 (2007), 6731–6741.
30. 30 Matsuoka, M., Jeang, K.T., Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 7 (2007), 270–280.
31. 31 Matsuoka, M., Green, P.L., The HBZ gene, a key player in HTLV-1 pathogenesis. Retrovirology, 6, 2009, 71.
32. 32 Bex, F., Gaynor, R.B., Regulation of gene expression by HTLV-I Tax protein. Methods 16 (1998), 83–94.
33. 33 Grassmann, R., Aboud, M., Jeang, K.T., Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 24 (2005), 5976–5985.
34. 34• Giam, C.Z., Semmes, O.J., HTLV-1 infection and adult T-cell leukemia/lymphoma-A tale of two proteins: tax and HBZ. Viruses, 8, 2016 The authors concisely summarize a large body of literature concerning how HTLV-1 infection progresses to ATL. They focus on the roles of two important viral proteins, Tax and HBZ, in viral replication, persistence, and oncogenesis.
35. 35• Kataoka, K., et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 47 (2015), 1304–1315 An integrated molecular study of 426 ATL cases was performed, identifying several alterations in the cellular genome which significantly overlap with the Tax interactome and are highly enriched for T-cell receptor-NF-κB signaling, T-cell trafficking and other T-cell-related pathways and immunosurveillance. These findings provide convincing evidence for new diagnostics and therapeutics in ATL patients.
36. 36 Satou, Y., et al. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci U S A 103 (2006), 720–725.
37. 37 Arnold, J., et al. Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of HTLV-1. Blood 107 (2006), 3976–3982.
38. 38 Arnold, J., et al. Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T lymphocyte proliferation. Blood 112 (2008), 3788–3797.
39. 39 Uchiyama, T., et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50 (1977), 81–492.
40. 40 Poiesz, B.J., et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 77 (1980), 7415–7419.
41. 41• Ishitsuka, K., Tamura, K., Human T-cell leukaemia virus type I and adult T-cell leukaemia–lymphoma. Lancet Oncol 15 (2014), e517–e526 The authors detail an updated determination of ATL clinical subtype classification according to the 1991 Shimoyama criteria. They also outline therapeutic options for ATL treatment outside of a clinical trial setting. Finally, current clinical trials for ATL which are ongoing or under consideration are reported.
42. 42 Ureshino, H., et al. Mogamulizumab for adult T-cell leukemia/lymphoma expressing atypical phenotype CD4−/CD8+/CCR4+. Open J Hematol, 5, 2014, 5.
43. 43 Shimoyama, M., Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia–lymphoma. A report from the lymphoma study group (1984–1987). Br J Haematol, 79, 1991, 437.
44. 44 Phillips, A.A., et al. A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer 116 (2010), 3438–3446.
45. 45 Ikeda, S., et al. Detection of preleukemic state of adult T-cell leukemia (pre-ATL) in HTLV-1 carriers. Cancer Detect Prev 14 (1990), 431–435.
46. 46 Orland, J.R., et al. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology 61 (2003), 1588–1594.
47. 47 Goncalves, D.U., et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev 23 (2010), 577–589.
48. 48 Bangham, C.R., Osame, M., Cellular immune response to HTLV-1. Oncogene 24 (2005), 6035–6046.
49. 49 Kamoi, K., Mochizuki, M., HTLV-1 uveitis. Front Microbiol, 3, 2012, 270.
50. 50 McGill, N.K., et al. HTLV-1-associated infective dermatitis: updates on the pathogenesis. Exp Dermatol 21 (2012), 815–821.
51. 51 Primo, J., et al. High HTLV-1 proviral load, a marker for HTLV-1 associated myelopathy/tropical spastic paraparesis, is also detected in patients with infective dermatitis associated with HTLV-1. Braz J Med Biol Res, Rev Bras Pesq Med Biol/Soc Brasil Biofis … [et al.] 42 (2009), 761–764.
52. 52 Nagai, M., et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 4 (1998), 586–593.
53. 53 Olindo, S., et al. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression. J Neurol Sci 237 (2005), 53–59.
54. 54 Tattermusch, S., et al. Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy. PLoS Pathogens, 8, 2012, e1002480.
55. 55 Iwanaga, M., et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 116 (2010), 1211–1219.
56. 56 Kikuchi, M., Jaffe, E.S., Ralfkiaer, E., Adult T-cell leukaemia/lymphoma. Jaffe, E.S., Harris, N.L., Stein, H., (eds.) WHO Classification of Tumours; Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 2001, IARC Press, Lyon, France, 200–203.
57. 57• Cook, L.B., et al. The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma. Blood 123 (2014), 3925–3931 Using a sensitive high-throughput method to quantify 197 ATL proviral integration sites, the authors quantified the oligoclonality in ATL and identified 91% of malignant clones contained a single provirus and that malignant clones mainly arise from low-abundance clones.
58. 58 Tsukasaki, K., et al. Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood 89 (1997), 948–956.
59. 59 Takasaki, Y., et al. Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res 31 (2007), 751–757.
60. 60 Gallamini, A., et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103 (2004), 2474–2479.
61. 61 Utsunomiya, A., et al. Adult T-cell leukemia with leukemia cell infiltration into the gastrointestinal tract. Cancer 61 (1988), 824–828.
62. 62 Tsukasaki, K., et al. Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: correlation with clinical course. Blood 97 (2001), 3875–3881.
63. 63 Itoyama, T., et al. Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood 97 (2001), 3612–3620.
64. 64 Tawara, M., et al. Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma. Cancer Lett 234 (2006), 249–255.
65. 65 Ramos, J.C., et al. IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood 109 (2007), 3060–3068.
66. 66 Kinpara, S., et al. Interferon-alpha (IFN-alpha) suppresses HTLV-1 gene expression and cell cycling, while IFN-alpha combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology, 10, 2013, 52.
67. 67 Tsukasaki, K., et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia–lymphoma: a proposal from an international consensus meeting. J Clin Oncol 27 (2009), 453–459.
68. 68 Takasaki, Y., et al. Long-term study of indolent adult T-cell leukemia–lymphoma. Blood 115 (2010), 4337–4343.
69. 69 Tsukasaki, K., et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia–lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25 (2007), 5458–5464.
70. 70• Ratner, L., et al. Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma. Blood cancer journal, 6, 2016, e408 The authors report favorable results of a current phase 1/2 trial which was designed to test the tolerability and efficacy of dose-adjusted EPOCH chemotherapy with bortezomib (proteasome inhibitor) and raltegravir (antiviral) in ATL patients.
71. 71 Ratner, L., et al. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia–lymphoma. PLoS ONE, 4, 2009, e4420.
72. 72 Gill, P.S., et al. Treatment of adult T-cell leukemia–lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332 (1995), 1744–1748.
73. 73 Hermine, O., et al. Brief report: treatment of adult T-cell leukemia–lymphoma with zidovudine and interferon alfa. N Engl J Med 332 (1995), 1749–1751.
74. 74 White, J.D., et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leukemia & lymphoma 40 (2001), 287–294.
75. 75 Bazarbachi, A., et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 28 (2010), 4177–4183.
76. 76 Fukushima, T., et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia 19 (2005), 829–834.
77. 77 Hishizawa, M., et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 116 (2010), 1369–1376.
78. 78• Kawada, H., et al. A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: a single-center experience. Biol Blood Marrow Transplant 21 (2015), 696–700 This retrospective study compared the effects of chemotherapy with alloHSCT for treatment of ATL. The authors found the use of alloHSCT is limited in chemorefractory patients with aggressive ATL disease, meaning chemosensitive patients were more receptive to alloHSCT and overall survival.
79. 79 Bomford, R., Kazanji, M., De The, G., Vaccine against human T cell leukemia–lymphoma virus type I: progress and prospects. AIDS Res Hum Retroviruses 12 (1996), 403–405.
80. 80 Rodriguez, S.M., et al. Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV. Viruses 3 (2011), 1210–1248.
81. 81 Suehiro, Y., et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. Br J Haematol 169 (2015), 356–367.
82. 82 Sugata, K., et al. Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor. Blood 126 (2015), 1095–1105.
83. 83 Panfil, A.R., Al-Saleem, J.J., Green, P.L., Animal models utilized in HTLV-1 research. Virol: Res Treat 4 (2013), 49–59.
84. 84 Villaudy, J., et al. HTLV-1 propels thymic human T cell development in “human immune system” Rag2(−)/(−) gamma c(−)/(−) mice. PLoS Pathogens, 7, 2011, e1002231.
85. 85 Aryee, K.E., Shultz, L.D., Brehm, M.A., Immunodeficient mouse model for human hematopoietic stem cell engraftment and immune system development. Methods Mol Biol 1185 (2014), 267–278.